贝伐单抗联合奥沙利铂与卡培他滨对胃癌患者的疗效及肠胃功能的影响

The Effect of Bevacizumab Combined with Oxaliplatin and Capecitabine on Gastric Cancer Patients and Gastrointestinal Function

目的:探讨贝伐单抗联合奥沙利铂与卡培他滨对胃癌患者的疗效及肠胃功能的影响.方法:选取2017年7月-2018年6月本院收治的胃癌患者108例.按照患者意愿将其分为对照组和研究组,每组54例.对照组给予5-氟尿嘧啶联合多西他赛与顺铂进行治疗,研究组给予贝伐单抗联合奥沙利铂与卡培他滨进行治疗.比较两组的临床效果、肠胃功能恢复情况、血清肿瘤标志物水平、不良反应发生情况及生活质量评分.结果:研究组治疗总有效率为75.9%,高于对照组的37.0%,差异有统计学意义(P<0.05).研究组初始进食时间、肠鸣音恢复时间、初次排气时间、排便时间、住院时间均短于对照组,差异均有统计学意义(P<0.05).治疗后,两组的血清肿瘤标志物水平均降低,且研究组的CA199、CEA、CA242水平均低于对照组,差异均有统计学意义(P<0.05).研究组的各项生活质量评分均高于对照组,差异均有统计学意义(P<0.05).研究组的不良反应发生率为35.2%,低于对照组的81.5%,差异有统计学意义(P<0.05).结论:对胃癌患者采用贝伐单抗联合奥沙利铂与卡培他滨治疗,其肠胃功能得到显著改善,同时提高了治疗的安全性及生活质量,值得推广应用.

Objective:To investigate the effect of Bevacizumab combined with Oxaliplatin and Capecitabine on gastric cancer patients and their gastrointestinal function.Method:A total of 108 patients with gastric cancer admitted to our hospital from July 2017 to June 2018 were selected.The patients were divided into control group and study group according to their wishes,54 cases in each group.The control group was treated with 5-fluorouracil combined with Docetaxel and Cisplatin,the study group was treated with Bevacizumab combined with Oxaliplatin and Capecitabine.The clinical effects,gastrointestinal function recovery,serum tumor markers,adverse reactions and quality of life scores of the two groups were compared.Result:The total effective rate of treatment in the study group was 75.9%,higher than 37.0%in the control group(P<0.05).The initial eating time,bowel sound recovery time,initial exhaust time,defecation time and hospital stay time of the study group were shorter than those of the control group,with statistically significant differences(P<0.05).After treatment,serum tumor markers in both groups were reduced,the CA199,CEA and CA242 levels in the study group were lower than those in the control group,with statistically significant differences(P<0.05).The quality of life scores of the study group were higher than those of the control group,the differences were statistically significant(P<0.05).The incidence of adverse reactions in the study group was 35.2%,lower than 81.5%in the control group,with a statistically significant difference(P<0.05).Conclusion:Patients with gastric cancer were treated with Bevacizumab,Oxaliplatin and Capecitabine,its gastrointestinal function has been significantly improved,while improving the safety and quality of life of the treatment,which is worth popularizing.